Plus   Neg

Kraft Heinz Sets Long-term Growth Targets - Quick Facts

While unveiling a transformation of the Company on Tuesday, Kraft Heinz Co. (KHC) updated its financial outlook for the third quarter and full-year 2020. It also established a long-term financial profile.

For the third quarter and fiscal 2020, the company now projects organic net sales growth in the mid-single-digit percentage range.

Kraft Heinz also set long-term growth targets. It projects long term organic net sales growth of 1 to 2 percent and adjusted earnings per share growth of 4 to 6 percent.

The new strategy, operating model and key initiatives signal a fundamental shift in its approach to growing its brands and its business at a global scale. This will enable Kraft Heinz to return to consistent and sustainable growth.

The new operating model focuses on five primary elements - People with Purpose, Consumer Platforms, Ops Center, Partner Program, and Fuel Our Growth. The company targets $2 billion in gross savings between 2020 and 2024 from efficiencies in Procurement, Manufacturing and Logistics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT